Cushing's Disease

21 registered clinical trials studyying Cushing's Disease — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	DDAVP for Pituitary Adenoma NCT04569591	National Institute of Neurological Disorders and Stroke (NINDS)	N/A
Withdrawn	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease NCT04339751	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2
Recruiting	A Trial of Lu AG13909 in Adult Participants With Cushing's Disease NCT06471829	H. Lundbeck A/S	Phase 2
Completed	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's NCT03346954	Hospices Civils de Lyon	N/A
Recruiting	Collecting Information About Treatment Results for Patients With Cushing's Syndrome NCT03364803	Memorial Sloan Kettering Cancer Center	—
Completed	Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease NCT02697734	Novartis Pharmaceuticals	Phase 3
Completed	Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease NCT02603653	Institut National de la Santé Et de la Recherche Médicale, France	N/A
Completed	Cushing's Disease Complications NCT02568982	Assistance Publique - Hôpitaux de Paris	—
Unknown	Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease NCT02484755	Huashan Hospital	Phase 2
Unknown	Seoul National University Pituitary Disease Cohort Study NCT03474601	Seoul National University Hospital	—
Completed	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegal NCT02060383	Novartis Pharmaceuticals	Phase 4
Withdrawn	Mifepristone in Children With Refractory Cushing's Disease NCT01925092	Corcept Therapeutics	Phase 3
Completed	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored NCT01794793	RECORDATI GROUP	Phase 4
Completed	Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease NCT01374906	Novartis Pharmaceuticals	Phase 3
Completed	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. NCT01582061	Novartis Pharmaceuticals	Phase 3
Completed	Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syn NCT01371565	Corcept Therapeutics	Phase 3
Unknown	Preoperative Bexarotene Treatment for Cushing's Disease NCT00845351	University of Virginia	Phase 1 / Phase 2
Terminated	Long-term Cardiovascular Risk in Cured Cushing's Patients NCT00881283	Massachusetts General Hospital	—
Completed	Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor NCT00889525	Seth Gordhandas Sunderdas Medical College	Phase 3
Terminated	Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) NCT00612066	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent NCT00434148	Novartis Pharmaceuticals	Phase 3